MGRX· Health Care› Health Information Services

Mangoceuticals, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Mangoceuticals is in Stage 4, the downtrend phase, now in week 2 (since Oct 12, 2026). It closed at $0.24, 89.7% below its 52-week high and below its 200-day average, which is falling.

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. More about the company

$0.24

-20.13% today

$5.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MGRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S? 20w

S4 19w

S4 16w

S4 21w

S4 28w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 20w → S4 19w → S1 11w → S2 1w → S1 1w → S2 2w → S3 6w → S4 16w → S1 8w → S2 3w → S3 1w → S4 21w → S1 10w → S4 28w → S1 4w → S4 3w → S1 11w → S2 1w → S4 2w current

Total tracked: 165 weeks across 19 stage runs.

MGRX among Health Information Services37th of 41 by relative strength

All 41 →

Stocks in Health Information Services ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	AMWLAmerican Well Corporation Class A	Stage 2 · wk 25	97	+7.4%
2	HNGEHinge Health, Inc. Class A	Stage 2 · wk 20	96	+19.1%
3	BTSGBrightSpring Health Services, Inc.	Stage 3 · wk 8	94	+9.1%
4	NRCNRC Health	Stage 3 · wk 4	93	−0.1%
5	SOPHSOPHiA GENETICS SA	Stage 2 · wk 24	91	−12.7%
6	HTFLHeartflow, Inc.	Stage 2 · wk 10	87	+17.0%
7	HSTMHealthStream, Inc.	Stage 2 · wk 17	77	+20.3%
8	OMCLOmnicell, Inc.	Stage 4 · wk 10	70	+12.5%
…37	MGRXMangoceuticals, Inc.	Stage 4 · wk 2	7	−45.7%

vs 52W High

-89.7%

$0.16 lo$2.37 hi

89.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-42.5%

200 DMA: $0.42 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.57x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-45.7%

-53.2%

-39.6%

YTD

-71.4%

-91.1%

Scan Membership

Breakout Watch

Latest: 2025-03-24

3 appearances in last 60 days. First seen: 2024-08-01.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.57x

2026-10-21S4

Wk 2 · Vol 0.05x

2026-10-20S4

Wk 2 · Vol 0.10x

2026-10-19S4

Wk 2 · Vol 0.42x

2026-10-16S4

Wk 1 · Vol 0.09x

2026-10-15S4

Wk 1 · Vol 0.16x

2026-10-14S4

Wk 1 · Vol 0.16x

2026-10-13S4

Wk 1 · Vol 0.07x

2026-10-12S42→4

Wk 1 · Vol 0.03x

2026-10-09S21→2

Wk 1 · Vol 0.03x

2026-10-08S1

Wk 12 · Vol 0.04x

2026-10-07S1

Wk 11 · Vol 0.04x

Moving averages & range

50 DMA

$0.41

200 DMA

$0.42

52W High

$2.37

52W Low

$0.16

5D Low

$0.24

Resistance levels (recent highs)

20d High

$0.48

60d High

$0.60

120d High

$0.60

250d High

$2.33

Next resistance

+97.1%

to 20d High

ROE

-95.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.4

Mangoceuticals: quick answers

What stage is Mangoceuticals in?

As of Oct 22, 2026, Mangoceuticals (MGRX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 12, 2026 and is in week 2. What the four stages mean

Is Mangoceuticals in an uptrend?

No. Mangoceuticals is in a Stage 4 downtrend. It trades 42.5% below its 200-day average, which is falling.

How far is Mangoceuticals from its 52-week high?

Mangoceuticals closed at $0.24 on Oct 22, 2026, 89.7% below its 52-week high of $2.37. Its 52-week low is $0.16.

How has Mangoceuticals performed over the past year?

As of Oct 22, 2026, Mangoceuticals is down 91.1% over the past year and down 71.4% so far in 2026.

Which sector and industry is Mangoceuticals in?

Mangoceuticals is in the Health Information Services industry, part of the Health Care sector.

About this companyHealth Care· Health Information Services

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.